CO45042 / KRAScendo 2

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).

ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT06793215?viewType=Card&id=co45042&rank=1

Locations: Hartford Hospital, Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut, Hartford HealthCare Medical Group - Manchester, Hartford HealthCare Cancer Institute - Avon, MidState Medical Center

Contact: Carissa Tipping: Carissa.Tipping@hhchealth.org